Dr. Reddy's Laboratories Announces 42nd AGM on July 23, 2026, Recommends Final Dividend
Dr. Reddy's Laboratories will hold its 42nd AGM on July 23, 2026. The company recommended a final dividend of ₹8 per equity share for FY2025-26. July 10, 2026, is the record date, and the dividend will be paid by July 30, 2026.
The announcement of the AGM and dividend is important for shareholders as it provides key dates and financial information.
The announcement is a routine corporate communication regarding the AGM and dividend, with no significant positive or negative financial news.
Dr. Reddy's Laboratories Limited has announced its 42nd Annual General Meeting (AGM) will be held on Thursday, July 23, 2026, at 11:00 a.m. IST through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The company has fixed Friday, July 10, 2026, as the record date for determining shareholders' entitlement to the final dividend for the financial year 2025-26.
The Board of Directors has recommended a final dividend of ₹8 per equity share of face value ₹1 each. This dividend, if approved by shareholders at the AGM, will be paid on or before July 30, 2026.
The company has also published a notice regarding the AGM, record date, and final dividend information in Business Standard and Nava Telangana, in compliance with SEBI regulations. Shareholders are advised to update their email addresses and bank details to ensure timely receipt of the annual report and dividend. The notice also details the tax implications, including Tax Deducted at Source (TDS) provisions for both resident and non-resident shareholders, and the required documentation for claiming lower withholding tax or exemptions under the Income Tax Act, 2025.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.